Literature DB >> 33591891

Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts.

Samuel Y Ash1, Raúl San José Estépar1, Sean B Fain1, Ruth Tal-Singer1, Robert A Stockley1, Lars H Nordenmark1, Stephen Rennard1, MeiLan K Han1, Debora Merrill1, Stephen M Humphries1, Alejandro A Diaz1, Stefanie E Mason1, Farbod N Rahaghi1, Carrie L Pistenmaa1, Frank C Sciurba1, Gonzalo Vegas-Sánchez-Ferrero1, David A Lynch1, George R Washko1.   

Abstract

Background The relationship between emphysema progression and long-term outcomes is unclear. Purpose To determine the relationship between emphysema progression at CT and mortality among participants with emphysema. Materials and Methods In a secondary analysis of two prospective observational studies, COPDGene (clinicaltrials.gov, NCT00608764) and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE; clinicaltrials.gov, NCT00292552), emphysema was measured at CT at two points by using the volume-adjusted lung density at the 15th percentile of the lung density histogram (hereafter, lung density perc15) method. The association between emphysema progression rate and all-cause mortality was analyzed by using Cox regression adjusted for ethnicity, sex, baseline age, pack-years, and lung density, baseline and change in smoking status, forced expiratory volume in 1 second, and 6-minute walk distance. In COPDGene, respiratory mortality was analyzed by using the Fine and Gray method. Results A total of 5143 participants (2613 men [51%]; mean age, 60 years ± 9 [standard deviation]) in COPDGene and 1549 participants (973 men [63%]; mean age, 62 years ± 8) in ECLIPSE were evaluated, of which 2097 (40.8%) and 1179 (76.1%) had emphysema, respectively. Baseline imaging was performed between January 2008 and December 2010 for COPDGene and January 2006 and August 2007 for ECLIPSE. Follow-up imaging was performed after 5.5 years ± 0.6 in COPDGene and 3.0 years ± 0.2 in ECLIPSE, and mortality was assessed over the ensuing 5 years in both. For every 1 g/L per year faster rate of decline in lung density perc15, all-cause mortality increased by 8% in COPDGene (hazard ratio [HR], 1.08; 95% CI: 1.01, 1.16; P = .03) and 6% in ECLIPSE (HR, 1.06; 95% CI: 1.00, 1.13; P = .045). In COPDGene, respiratory mortality increased by 22% (HR, 1.22; 95% CI: 1.13, 1.31; P < .001) for the same increase in the rate of change in lung density perc15. Conclusion In ever-smokers with emphysema, emphysema progression at CT was associated with increased all-cause and respiratory mortality. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Lee and Park in this issue.

Entities:  

Mesh:

Year:  2021        PMID: 33591891      PMCID: PMC7997617          DOI: 10.1148/radiol.2021203531

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  33 in total

1.  Short-term effect of changes in smoking behaviour on emphysema quantification by CT.

Authors:  Haseem Ashraf; Pechin Lo; Saher Burhan Shaker; Marleen de Bruijne; Asger Dirksen; Philip Tønnesen; Magnus Dahlbäck; Jesper Holst Pedersen
Journal:  Thorax       Date:  2010-10-26       Impact factor: 9.139

2.  Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort.

Authors:  Hester A Gietema; Nestor L Müller; Paola V Nasute Fauerbach; Sanjay Sharma; Lisa D Edwards; Pat G Camp; Harvey O Coxson
Journal:  Acad Radiol       Date:  2011-03-09       Impact factor: 3.173

3.  COPD comorbidities network.

Authors:  Miguel J Divo; Ciro Casanova; Jose M Marin; Victor M Pinto-Plata; Juan P de-Torres; Javier J Zulueta; Carlos Cabrera; Jorge Zagaceta; Pablo Sanchez-Salcedo; Juan Berto; Rebeca Baz Davila; Ana B Alcaide; Claudia Cote; Bartolome R Celli
Journal:  Eur Respir J       Date:  2015-07-09       Impact factor: 16.671

4.  Genetic epidemiology of COPD (COPDGene) study design.

Authors:  Elizabeth A Regan; John E Hokanson; James R Murphy; Barry Make; David A Lynch; Terri H Beaty; Douglas Curran-Everett; Edwin K Silverman; James D Crapo
Journal:  COPD       Date:  2010-02       Impact factor: 2.409

5.  Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials.

Authors:  MeiLan K Han; Nabihah Tayob; Susan Murray; Prescott G Woodruff; Jeffrey L Curtis; Victor Kim; Gerard Criner; Craig J Galban; Brian D Ross; Eric A Hoffman; David A Lynch; Ella Kazerooni; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

6.  Emphysema produced in dogs by cigarette smoking.

Authors:  O Auerbach; E C Hammond; D Kirman; L Garfinkel
Journal:  JAMA       Date:  1967-01-23       Impact factor: 56.272

7.  Monitoring the progress of emphysema by repeat computed tomography scans with focus on noise reduction.

Authors:  Asger Dirksen
Journal:  Proc Am Thorac Soc       Date:  2008-12-15

8.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE).

Authors:  J Vestbo; W Anderson; H O Coxson; C Crim; F Dawber; L Edwards; G Hagan; K Knobil; D A Lomas; W MacNee; E K Silverman; R Tal-Singer
Journal:  Eur Respir J       Date:  2008-01-23       Impact factor: 16.671

9.  "Density mask". An objective method to quantitate emphysema using computed tomography.

Authors:  N L Müller; C A Staples; R R Miller; R T Abboud
Journal:  Chest       Date:  1988-10       Impact factor: 9.410

Review 10.  Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.

Authors:  Suher Othman Abu Hassaan
Journal:  Dan Med J       Date:  2018-04       Impact factor: 1.240

View more
  3 in total

Review 1.  Quantitative Computed Tomography: What Clinical Questions Can it Answer in Chronic Lung Disease?

Authors:  Marcelo Cardoso Barros; Stephan Altmayer; Alysson Roncally Carvalho; Rosana Rodrigues; Matheus Zanon; Tan-Lucien Mohammed; Pratik Patel; Al-Ani Mohammad; Borna Mehrad; Jose Miguel Chatkin; Bruno Hochhegger
Journal:  Lung       Date:  2022-06-25       Impact factor: 3.777

2.  Emphysema Progression at CT by Deep Learning Predicts Functional Impairment and Mortality: Results from the COPDGene Study.

Authors:  Andrea S Oh; David Baraghoshi; David A Lynch; Samuel Y Ash; James D Crapo; Stephen M Humphries
Journal:  Radiology       Date:  2022-05-17       Impact factor: 29.146

3.  Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPDGene Cohort.

Authors:  Vickram Tejwani; Ashraf Fawzy; Nirupama Putcha; Peter J Castaldi; Michael H Cho; Katherine A Pratte; Surya P Bhatt; David A Lynch; Stephen M Humphries; Gregory L Kinney; Franco R D'Alessio; Nadia N Hansel
Journal:  Chest       Date:  2021-05-21       Impact factor: 10.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.